Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
64 hedge funds and large institutions have $21.4M invested in Northwest Biotherapeutics, Inc. Common stock in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.03% less ownership
Funds ownership: 41.35% → 32.32% (-9%)
14% less funds holding
Funds holding: 74 → 64 (-10)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
62% less call options, than puts
Call options by funds: $132K | Put options by funds: $347K
65% less capital invested
Capital invested by funds: $61.5M → $21.4M (-$40.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$491K |
| 2 |
Goldman Sachs
New York
|
+$341K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$300K |
| 4 |
Renaissance Technologies
New York
|
+$282K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.6M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.44M |
| 3 |
State Street
Boston,
Massachusetts
|
-$879K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$477K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$468K |
NWBO Hedge Fund Activity: Q2 2016 in Review
64 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2016, worth a combined $21.4M — down 65% from $61.5M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of NWBO and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $491K. The largest seller was Sabby Management, cutting an estimated $2.6M.
- 64 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2016, down from 74 in Q1 2016.
- Funds reported $21.4M of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2016, down 65% quarter-over-quarter.
- 16 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2016 and 26 closed out, a net change of -10 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2016 was Millennium Management, an estimated $491K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2016 was Sabby Management, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2016.